Diffuse intrinsic pontine gliomas (DIPG) - Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Diffuse Intrinsic Pontine Gliomas (DIPG)

Epidemiology study suggests Incidence is 1 to 2 cases per 100,000 population. DIPG has a peak incidence of 6-9 years and a slight preference for males. Among all the tumors in children, they represent 20% of them.

KOLs insights DIPG across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of diffuse intrinsic pontine gliomas (DIPG) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Market Forecasting - Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event , Country specific Forecast Model , Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario , Summary and Insights.

Read more: Diffuse intrinsic pontine gliomas (DIPG) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 S.N.        Asset        Company        Stage

1        Drug: BXQ-350        Bexion Pharmaceuticals, Inc.        Phase 1

2        Drug: PTC596        PTC Therapeutics        Phase 1

3        Drug: Temozolomide        Genentech, Inc.        Phase 1

4        Drug: ONC201        Chimerix        Phase 1

5        Drug: Panobinostat Nanoparticle Formulation MTX110        Midatech Pharma US Inc.        Phase 2

6        Drug: DSP-7888        Sumitomo Dainippon Pharma Co., Ltd.        Phase 2

7        Biological: Ad-RTS-hIL-12        Ziopharm        Phase 2

8        Drug: Crenolanib        Arog Pharmaceuticals, Inc.        Phase 1

9        Biological: DNX-2401        DNAtrix, Inc.        Phase 1

10        Biological: DNX-2401        Alcyone Lifesciences, Inc.        Phase 1

11        Drug: GDC-0084        Kazia Therapeutics Limited        Phase 1

12        Drug: REGN2810        Regeneron Pharmaceuticals        Phase 2

13        Drug: Marizomib        Celgene        Phase 1

14        Drug: Mebendazole        Janssen Pharmaceuticals        Phase 2

15        Drug: ribociclib        Novartis        Phase 1

16        Drug: Indoximod        NewLink Genetics Corporation        Phase 1

17        Drug: Indoximod        Lumos Pharma        Phase 1

18        Drug: Palbociclib        Pfizer        Phase 1

19        Drug: 9-ING-41        Actuate Therapeutics Inc.        Phase 1

20        Biological: Nivolumab        Bristol-Myers Squibb        Phase 2

21        Biological: NKTR-214        Nektar Therapeutics        Phase 2

22        Drug: Depatuxizumab mafodotin        AbbVie        Phase 2

23        Drug: Abemaciclib        Eli Lilly and Company        Phase 1

24        Drug: CLR 131        Cellectar Biosciences, Inc.        Phase 1